Smart T-Cell engager aims to outsmart tumors in first human test
Disease control
Not yet recruiting
This early-phase trial tests an experimental drug, KGX105, in people with advanced solid tumors that have not responded to standard treatments. KGX105 is designed to activate immune T-cells specifically within the tumor, potentially reducing side effects. The study will assess sa…
Phase: PHASE1 • Sponsor: Kangabio AUSTRALIA LTD PTY • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC